RVX Stock Financial Analysis - Resverlogix Corp. (TSX) Stock

Overview

Resverlogix Corp. is a biotechnology firm based in Canada, specializing in the development of innovative therapies primarily focusing on patients with cardiovascular disease, diabetes mellitus, and chronic kidney disease. At the core of its clinical development is apabetalone (RVX-208), a novel small molecule that regulates protein transcription to address severe unmet medical needs. Apabetalone is at the forefront of Resverlogix's projects, progressing through advanced clinical trials aimed at demonstrating its efficacy in reducing major adverse cardiac events. The company leverages its proprietary epigenetic platform technology that uniquely controls gene expression, emphasizing its commitment to leading-edge cardiovascular and epigenetic research to improve patient outcomes on a global scale.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The operating income for Resverlogix Corp. as of June 30, 2025 is -4.82 MM.
The net income for Resverlogix Corp. as of June 30, 2025 is -11.08 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30		-4.82	-11.08
2025-03-31		-4.61	-13.98
2024-12-31		-4.60	-7.63
2024-09-30		-4.27	-11.23
2024-06-30		-4.32	-10.74
2024-03-31		-4.70	-10.25
2023-12-31		-5.18	-16.74
2023-09-30		-5.37	-12.82
2023-06-30		-6.48	-10.04
2023-03-31		-7.08	-6.43
2022-12-31		-11.43	-3.61
2022-09-30		-15.77	-21.31
2022-06-30		-18.79	-24.92
2022-03-31		-20.15	-27.12
2021-12-31		-15.94	-24.77
2020-12-31		-14.57	2.46
2020-10-31		-12.75	3.77
2020-07-31
2020-04-30

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31
2024-09-30	-0.04	-0.04
2024-06-30	-0.04	-0.04
2024-03-31	-0.04	-0.04
2023-12-31	-0.06
2023-09-30	-0.05	-0.05
2023-06-30	-0.04	-0.04
2023-03-31	-0.02	-0.03
2022-12-31	-0.01
2022-09-30	-0.09	-0.09
2022-06-30	-0.10	-0.10
2022-03-31	-0.11	-0.11
2021-12-31	-0.10	-0.10
2020-12-31	0.01	0.02
2020-10-31	0.02	0.02
2020-07-31	0.51	0.51
2020-04-30	0.57	0.54

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Resverlogix Corp. as of June 30, 2025 is -2.96 MM.
The cash from investing activities for Resverlogix Corp. as of June 30, 2025 is -0.45 MM.
The cash from financing activities for Resverlogix Corp. as of June 30, 2025 is 3.37 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-2.96	-0.45	3.37
2025-03-31	-3.00	-0.36	3.46
2024-12-31	-3.89	-0.38	4.36
2024-09-30	-3.93	-0.43	4.31
2024-06-30	-3.92	-0.46	4.36
2024-03-31	-3.73	-0.49	4.28
2023-12-31	-2.51	-0.52	2.99
2023-09-30	-1.66	-0.52	2.26
2023-06-30	-2.67	-0.53	3.25
2023-03-31	-3.03	-0.54	3.11
2022-12-31	-3.63	-0.47	4.15
2022-09-30	-4.06	-0.37	4.06
2022-06-30	-4.98	-0.37	2.20
2022-03-31	-9.03	-0.93	10.44
2021-12-31	-8.02	-0.83	8.81
2020-12-31	-4.40	-0.43	4.95
2020-10-31	-3.95	-0.53	4.36
2020-07-31
2020-04-30

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2020-12-31
2020-10-31
2020-07-31
2020-04-30

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2020-12-31
2020-10-31
2020-07-31
2020-04-30

Management Effectiveness

The roa for Resverlogix Corp. as of June 30, 2025 is -1.84.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-1.84
2025-03-31	-1.51
2024-12-31	-1.72
2024-09-30	-1.37
2024-06-30	-1.29
2024-03-31	-1.58
2023-12-31	-1.25
2023-09-30	-1.00
2023-06-30	-0.36
2023-03-31	-2.07
2022-12-31	-1.89
2022-09-30	-2.21
2022-06-30	-1.92
2022-03-31	0.00
2021-12-31	0.00				0.00
2020-12-31	0.18
2020-10-31	5.43
2020-07-31	5.43
2020-04-30	7.25

Gross Margins

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2020-12-31
2020-10-31
2020-07-31
2020-04-30

GB:0VF9
US:RVXCF
DE:RFS	€0.06